UK emerging pharmaceutical company Xenova is forming a new company, MetaXen, which will be located in California in the USA. The new firm will play a key role in Xenova Preclinical, a new division.
MetaXen's initial objectives are to: expand Xenova's drug lead optimization technologies and apply them to accelerate the conversion of Xenova's drug leads into valuable candidate drugs; establish a structure-based drug design group with capabilities in combinatorial and computational chemistry and crystallography, to complement the existing medicinal chemistry group at Xenova in the UK; establish an in vitro metabolism and drug absorption group to create high-throughput assays, which will help predict in vivo behavior of compounds and complement Xenova's existing in vivo pharmacology activities in the UK; apply genomics, transgenic animal models and bioinformatics to enhance Xenova's target technology for the identification of important new therapeutic targets; and engage in new collaborations with pharmaceutical companies on MetaXen drug leads.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze